Abstract A106: A phase 1 study of ENMD‐2076 in patients with relapsed or refractory acute myeloid leukemia (AML)

Randomized phase 1 study of sequential (“primed”) vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm

Leukemia & Lymphoma ◽

10.1080/10428194.2020.1728754 ◽

2020 ◽

Vol 61 (7) ◽

pp. 1728-1731

Author(s):

Raffaele Palmieri ◽

Sarah A. Buckley ◽

Megan Othus ◽

Anna B. Halpern ◽

Mary-Elizabeth M. Percival ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Phase 1 ◽

High Grade ◽

Newly Diagnosed ◽

Phase 1 Study ◽

Myeloid Neoplasm ◽

Phase 1 study of CWP232291 in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.7044 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 7044-7044 ◽

Cited By ~ 11

Author(s):

Jorge E. Cortes ◽

Stefan Faderl ◽

John Pagel ◽

Chul Won Jung ◽

Sung-Soo Yoon ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Myelodysplastic Syndrome ◽

Myeloid Leukemia ◽

Phase 1 ◽

Phase 1 Study ◽

Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study

Cancer Science ◽

10.1111/cas.13749 ◽

2018 ◽

Vol 109 (10) ◽

pp. 3235-3244 ◽

Cited By ~ 23

Author(s):

Kensuke Usuki ◽

Toru Sakura ◽

Yukio Kobayashi ◽

Toshihiro Miyamoto ◽

Hiroatsu Iida ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Phase 1 ◽

Japanese Patients ◽

Clinical Profile ◽

Open Label ◽

Phase 1 Study ◽

Open Label Phase ◽

A phase 1 study of the pan‐bromodomain and extraterminal inhibitor mivebresib (ABBV‐075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia

Cancer ◽

10.1002/cncr.33590 ◽

2021 ◽

Author(s):

Gautam Borthakur ◽

Olatoyosi Odenike ◽

Ibrahim Aldoss ◽

David A. Rizzieri ◽

Thomas Prebet ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Phase 1 ◽

Phase 1 Study ◽

Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study

International Journal of Hematology ◽

10.1007/s12185-019-02709-8 ◽

2019 ◽

Vol 110 (6) ◽

pp. 654-664 ◽

Cited By ~ 2

Author(s):

Kensuke Usuki ◽

Hiroshi Handa ◽

Ilseung Choi ◽

Takahiro Yamauchi ◽

Hiroatsu Iida ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Phase 1 ◽

Japanese Patients ◽

Phase 1 Study ◽

Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes

Annals of Hematology ◽

10.1007/s00277-021-04734-2 ◽

2022 ◽

Author(s):

Amer M. Zeidan ◽

Daniel J. DeAngelo ◽

Jeanne Palmer ◽

Christopher S. Seet ◽

Martin S. Tallman ◽

...

Keyword(s):

Monoclonal Antibody ◽

Acute Myeloid Leukemia ◽

High Risk ◽

Myelodysplastic Syndromes ◽

Myeloid Leukemia ◽

Phase 1 ◽

Phase 1 Study ◽

Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2018.07.057 ◽

2018 ◽

Vol 18 ◽

pp. S204-S205 ◽

Cited By ~ 1

Author(s):

Courtney D. DiNardo ◽

Eytan M. Stein ◽

Stéphane de Botton ◽

Gail J. Roboz ◽

Jessica K. Altman ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Phase 1 ◽

Phase 1 Study ◽

Mutant Idh1 ◽

A phase 1 study of the antibody‐drug conjugate brentuximab vedotin with re‐induction chemotherapy in patients with CD30‐expressing relapsed/refractory acute myeloid leukemia

Cancer ◽

10.1002/cncr.32657 ◽

2019 ◽

Vol 126 (6) ◽

pp. 1264-1273 ◽

Cited By ~ 7

Author(s):

Rupa Narayan ◽

Traci M. Blonquist ◽

Ashkan Emadi ◽

Robert P. Hasserjian ◽

Meghan Burke ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Induction Chemotherapy ◽

Myeloid Leukemia ◽

Phase 1 ◽

Brentuximab Vedotin ◽

Antibody Drug Conjugate ◽

Phase 1 Study ◽

Acute Myeloid ◽

Antibody Drug

24 / Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study

10.26226/morressier.5b3b802cb1b87b000eced98e ◽

2018 ◽

Cited By ~ 1

Author(s):

DiNardo Courtney D

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Phase 1 ◽

Phase 1 Study ◽

Mutant Idh1 ◽

Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.7000 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 7000-7000 ◽

Cited By ~ 1

Author(s):

Daniel Aaron Pollyea ◽

Courtney Denton Dinardo ◽

Stéphane de Botton ◽

Eytan Stein ◽

Gail J. Roboz ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Phase 1 ◽

Phase 1 Study ◽

Mutant Idh1 ◽